| 2024-02-01 | Sale | Travere Therapeutics, Inc. TVTX | CHIEF COMMERCIAL OFFICER | 4,195 0.0053% | $8.53 | $35,789 | -15.81% | |
| 2024-01-23 | Sale | Travere Therapeutics, Inc. TVTX | CHIEF COMMERCIAL OFFICER | 1,559 0.002% | $9.07 | $14,138 | -20.65% | |
| 2023-10-03 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 3,091 0.004% | $8.25 | $25,504 | -14.21% | |
| 2023-02-01 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,779 0.0026% | $21.75 | $38,697 | -30.53% | |
| 2023-01-24 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,550 0.0023% | $21.90 | $33,952 | -28.72% | |
| 2022-10-04 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 3,042 0.0047% | $25.68 | $78,119 | ||
| 2022-01-31 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,125 0.0018% | $27.40 | $30,825 | -11.82% | |
| 2022-01-24 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,875 0.0029% | $24.98 | $46,838 | -5.13% | |
| 2021-10-04 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 3,058 0.0051% | $24.77 | $75,746 | +5.78% | |
| 2021-08-17 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,407 0.002% | $17.12 | $24,086 | +30.66% | |
| 2021-02-08 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,125 0.002% | $31.58 | $35,528 | -19.42% | |
| 2021-02-05 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 1,125 0.002% | $31.41 | $35,336 | -21.33% | |
| 2021-02-03 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 563 0.001% | $28.91 | $16,276 | -17.7% | |
| 2021-02-02 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 563 0.0011% | $30.75 | $17,312 | -13.09% | |
| 2020-10-05 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 2,188 0.0044% | $19.35 | $42,338 | +16.94% | |
| 2020-10-02 | Sale | Travere Therapeutics, Inc. TVTX | Chief Commercial Officer | 2,188 0.0045% | $18.90 | $41,353 | +22.88% |